Helping Clients/Patients Meet Targets with GLP-1 and GIP/GLP-1 Receptor Agonists with Christie Schumacher
Christie Schumacher PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, joins The Huddle to talk through the use of GLP-1 and GIP/GLP-1 receptor agonists for your people with type 2 diabetes. You’ll learn what medications fall into the class of GLP-1 and GIP/GLP-1 receptor agonists, how they work and the benefits they can offer people with type 2 diabetes. These medications can be a useful tool in the therapeutic toolkit as highlighted in the recently updated ADA/EASD consensus statement, so this episode will offer practical considerations when initiating GLP-1 and GIP/GLP-1 receptor agonists in patients and managing possible side effects.
We want to thank our sponsor, Lilly Diabetes, for their support of this episode.
VV-MED-128766 ©2022 Lilly USA, LLC. All rights reserved
- ADA and EASD Consensus Report for the Management of Hyperglycemia in Type 2 Diabetes, 2022: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetes Care | American Diabetes Association (diabetesjournals.org)
- ADCES Incretin-Based therapies tip sheet: DiabetesEducator.org/docs/default-source/living-with-diabetes/tip-sheets/medication-taking/incretin-based_therapies_tip_sheet_1006202291a90b03-fff9-4b81-98c9-42ef98f0c501.pdf
- Episode Transcript: DiabetesEducator.org/docs/default-source/podcast-docs/incretin-full-show.docx
- Medication Taking Resources from ADCES: 1) For healthcare professionals: DiabetesEducator.org/MedicationTaking 2) For people with diabetes: DiabetesEducator.org/TakingMedication